Product Description
SARS-CoV-2 Spike P681H Antibody (Alpha, Mu Variant) | 9359 | ProSci
Host: Rabbit
Reactivity: Virus
Homology: Predicted reactivity based on immunogen sequence: SARS-CoV Spike proteins: (25%)
Immunogen: Anti-SARS-CoV-2 (COVID-19) P681H Mutant Specific Spike P681H Antibody (9359) was raised against a peptide corresponding to 12 amino acids near the center of SARS-CoV-2 UK variant (B.1.1.7) Spike protein.
The immunogen is located within 650-700 amino acids of SARS-CoV-2 UK variant (B.1.1.7) Spike protein.
Research Area: Infectious Disease, COVID-19
Tested Application: E, WB
Application: WB: 1 μg/mL.
Antibody validated: Western Blot in human samples. Anti-SARS-CoV-2 (COVID-19) P681H Mutant Specific Spike antibody can specifically detect SARS-CoV-2 UK Variant (B.1.1.7) Spike S1 protein, but not SARS-CoV-2 WT Spike S1 protein by ELISA. It can also detect mutant peptide (681H) , but not WT peptide (681P) . All other applications and species not yet tested.
Specificiy: May cross-react with several virus of interest (VOI) variant lineages that contains P681H mutation, including B.11.318, B.1.621, B.1.621.1, P.3. But all of these lineages are rarely present in current pandemic.
Positive Control 1: N/A
Positive Control 2: N/A
Positive Control 3: N/A
Positive Control 4: N/A
Positive Control 5: N/A
Positive Control 6: N/A
Molecular Weight: N/A
Validation: N/A
Isoform: N/A
Purification: SARS-CoV-2 (COVID-19) Alpha Variant (B.1.1.7, UK) Spike P681H Antibody is affinity chromatography purified via peptide column.
Clonality: Polyclonal
Clone: N/A
Isotype: IgG
Conjugate: Unconjugated
Physical State: Liquid
Buffer: SARS-CoV-2 (COVID-19) P681H Mutant Specific Spike antibody is supplied in PBS containing 0.02% sodium azide.
Concentration: 1 mg/mL
Storage Condition: SARS-CoV-2 (COVID-19) P681H Mutant Specific Spike antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
Alternate Name: SARS-CoV-2 (COVID-19) Spike Antibody: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) , Surface Glycoprotein, Spike protein
User Note: Optimal dilutions for each application to be determined by the researcher.
BACKGROUND: In September of 2020 a new lineage of SARS-CoV-2, known as B.1.1.7, was discovered in the United Kingdom. This lineage was found to have developed 14 lineage-specific amino acid replacements and 3 deletions prior to its discovery. The transmission of UK variant (B.1.1.7 lineage) was increased at least 50%. Increased severity and higher death rate were also found in UK variant. UK variant will not affect the effectiveness of COVID19 vaccine. One of the mutations associated with this lineage is a N501Y in the spike protein of the virus. It is believed that this mutation is able to increase the spike protein's affinity for the host ACE2 receptor and it has been associated with increased infectivity and virulence. B.1.1.7 viruses have also been shown to have a P681H in the cleavage site of spike protein. This location is one of the residues that make up the furin cleavage site between S1 and S2 in spike protein.